Results 151 to 160 of about 5,494 (193)
Quality Gaps in Online Media Coverage of Antiamyloid Monoclonal Antibodies for Alzheimer Disease.
JAMA Netw OpenMacedo AC +8 more
europepmc +1 more source
Aducanumab: Appropriate Use Recommendations [PDF]
journal of prevention of Alzheimer's disease, The, 2021 Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based on the participant populations, conduct of the pivotal trials of aducanumab, updated ...
Jeffrey L. Cummings +2 more
exaly +11 more sources
Aducanumab: Appropriate Use Recommendations Update [PDF]
journal of prevention of Alzheimer's disease, The, 2022 Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab.
Jeffrey L. Cummings +2 more
exaly +6 more sources
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
International Journal of Molecular Sciences, 2023 In June 2021, the world was informed about a new drug for Alzheimer’s disease approved by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest AD treatment. The activity of the drug is targeted towards amyloid β, which is considered one of the main causes of Alzheimer’s disease.
Karolina Wojtunik-Kulesza
exaly +5 more sources
Neurotherapeutics, 2023 Immunotherapy against amyloid-beta (A ss) is a promising option for the treatment of Alzheimer's disease ( AD). A ss exists as various species, including monomers, oligomers, protofibrils, and insoluble fibrils in plaques. Oligomers and protofibrils have
Lars Lannfelt +2 more
exaly +2 more sources